Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | WDR5 | P61964 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1227806 | 0.93 | CHRM1 (0.42) | CHRM1KCNH2WDR5NPC1RAB9A | |
| SCHEMBL1227882 | 0.91 | CHRM1 (0.47) | CHRM1KCNH2WDR5NPC1RAB9A | |
| SCHEMBL16319782 | 0.85 | CHRM1 (0.41) | CHRM1KCNH2LMNA | |
| SCHEMBL1228519 | 0.85 | CHRM1 (0.59) | CHRM1KCNH2GRM2 | |
| SCHEMBL13280996 | 0.85 | NPC1 (0.43) | NPC1RAB9AMEN1KMT2AHRH3 | |
| SCHEMBL1228646 | 0.84 | CHRM1 (0.47) | CHRM1KCNH2WDR5NPC1RAB9A | |
| SCHEMBL1227270 | 0.83 | CHRM1 (0.56) | CHRM1KCNH2GRM2MAPT | |
| SCHEMBL16319648 | 0.82 | CHRM1 (0.35) | CHRM1KCNH2MEN1KMT2ALMNA | |
| SCHEMBL1227363 | 0.80 | CHRM1 (0.47) | CHRM1KCNH2CYP19A1 | |
| SCHEMBL15442757 | 0.80 | PTGS1 (0.40) | CHRM1KCNH2GRM2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459570-B1 | NITROIMIDAZOOXAZINE ANALOGUES AND THEIR USES | GLOBAL ALLIANCE FOR TB DRUG DEV (US) | 2014-12-24 | — | — | EP | claimed |
| US-8293734-B2 | Nitroimidazooxazine and nitroimidazooxazole analogues and their uses | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2012-10-23 | — | — | US | claimed |
| US-20110028466-A1 | NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2011-02-03 | — | — | US | claimed |
| EP-2459570-B1 | NITROIMIDAZOOXAZINE ANALOGUES AND THEIR USES | GLOBAL ALLIANCE FOR TB DRUG DEV (US) | 2014-12-24 | — | — | EP | disclosed |
| EP-2459570-B1 | NITROIMIDAZOOXAZINE ANALOGUES AND THEIR USES | GLOBAL ALLIANCE FOR TB DRUG DEV (US) | 2014-12-24 | — | — | EP | disclosed |
| US-8293734-B2 | Nitroimidazooxazine and nitroimidazooxazole analogues and their uses | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293734-B2 | Nitroimidazooxazine and nitroimidazooxazole analogues and their uses | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293734-B2 | Nitroimidazooxazine and nitroimidazooxazole analogues and their uses | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2012-10-23 | — | — | US | disclosed |
| WO-2011014776-A1 | NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2011-02-03 | — | — | WO | disclosed |
| US-20110028466-A1 | NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2011-02-03 | — | — | US | disclosed |
| US-20110028466-A1 | NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2011-02-03 | — | — | US | disclosed |
| US-20110028466-A1 | NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028466-A1 | NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES | NOX5, NQO2, SIRT5 | CHRM1 1308/4885KCNH2 2847/4885WDR5 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.